Vaccine Congress West Coast 2023 Agenda

Santa Clara, CA, 27 - 30 November 2023

Schedule

Create your personal agenda –check the favourite icon

Nov 2714:00
Conference pass

Workshop A - Antibodies: Discovery vs Computational Design

Pre-congress workshops

Series of presentations followed by panel discussion

Computational design of antibodies-Dr Daniel Faissol, Principal Investigator, Center for Bioengineering, Executive Director, Predictive Design of Biologics, Lawrence Livermore National Laboratory

Discovery & development of broad-spectrum antibodies for Flu, COVID & RSV-Dr Phillip Lovanti,Sr. Director of R&D, Aridis Pharmaceuticals

Machine learning models for design of antibodies -Dr Sai Pooja Mahajan, Senior Scientist, Prescient Design, Genentech

Computational and artificial intelligence-based methods for antibody development -Dr Philip Kim, Professor, Principal Investigator, Department of Molecular Genetics, University of Toronto

How are NITAGs & HTAs thinking about novel antibody products? Richard Hughes, Partner, Epstein, Becker & Green, Professorial Lecturer in Law, The George Washington University Law School

M1
Nov 2714:00
Conference pass

Workshop B - Infodemiology as a means to engage with health care and public health

Pre-congress workshops

Infodemiology as a means to engage with health care and public health

This session is part program launch, and part interactive workshop. The U.S. "House of Medicine" represents all national medical boards in the country. Led by the American Board of Internal Medicine (ABIM) and public health nonprofit PGP, the House of Medicine has launched the Health Care Infodemiology Brief. Infodemiology is the study of information's impact on health, particularly online information. Vaccine confidence is driving the adoption of infodemiology. This resource helps clinicians better understand trending health narratives and debunk false claims to which their patients may have been exposed. The Health Care Infodemiology Brief examines vaccines and other topics that are the subjects of most false claims found on social media and online.

This workshop will introduce participants to the Health Care Infodemiology Brief, its parent program integrating infodemiology throughout health care, and its sister programs integrating media monitoring, analyses, and reporting throughout public health. Mitigating the impact of vaccine misinformation and increasing vaccine confidence is a central focus of these programs.

Following this overview, workshop participants will be shown how infodemiology works in practice. Live dashboards of public conversations, examples of misinformation, and exercises to think through communications and reporting will be conducted. PGP experts are frequent speakers at WVC events and have deep knowledge of current pharmaceutical industry efforts to support health care and public health. They know what they're talking about and enjoy what they do. Stop on by!

M2

Create your personal agenda –check the favourite icon

Nov 288:25
Conference pass

Opening Keynote: Cracking the code of immunity: The latest breakthroughs in systems immunology for uncovering the secrets of human immunity to vaccines and infections

Keynotes
HALL B
Nov 288:50
Conference pass

Keynote presentation: Lessons from the pandemic: ensuring a bright future for vaccine development, administration, and confidence

Keynotes
HALL B
Nov 2810:10
Conference pass

Keynote Panel: Navigating the future of RSV Vaccines & Therapies: Tailoring Approaches from Maternal to Adults

Keynotes
  • Now there are vaccines available, what is the right approach for adults vs infants & maternal?
  • What is the optimal recommendation for use of different technologies based on the epidemiology of the disease?
  • Practical issues, health economics & policy considerations
  • Cost-effectiveness challenges
  • Remaining needs in older adults; how to protect in the second season and beyondHow to combat vaccine fatigue with new combinations and other approaches
  • The ecosystem of respiratory tract infections in the absence of RSV
HALL B
Nov 2811:10
Conference pass

Exhibition & Partnering Break - Morning

Keynotes

Tea, Coffee and Refreshments served in the exhibition area

One-to-one networking meetings, Poster Presentations

So you can plan ahead there will be a Café station open in the exhibition from 8am-5pm where you can purchase tea, coffee and pastries until 11am, and then purchase hot food till 3pm.There will also be another open from 11am-3pm where you can purchase salads, sandwiches, drinks and other snacks

HALL A
Nov 2811:45
Conference pass

Roundtable 1. Ensuring clinical trial enrollment, retention, and diversity

Interactive Roundtables
M1
Nov 2811:45
Conference pass

Roundtable 2. Incorporating post-viral diseases into your company’s clinical & market strategy

Interactive Roundtables
M2
Nov 2811:45
Conference pass

Roundtable 3. Stand out from the crowd - How can biotechs grab investors’ attention?

Interactive Roundtables
M3
Nov 2811:45
Conference pass

Roundtable 4. The policy & politics of vaccine mandates in California and around the world

Interactive Roundtables
B4
Nov 2811:45
Conference pass

Roundtable 5. Partnerships to advance diverse leadership pipelines in biotechnology companies

Interactive Roundtables
B5
Nov 2812:30
Conference pass

Exhibition & Partnering Break - Lunch

Keynotes

One-to-one networking meetings, Poster Presentations

So you can plan ahead there will be a Café station open in the exhibition from 8am-5pm where you can purchase tea, coffee and pastries until 11am, and then purchase hot food till 3pm.There will also be another open from 11am-3pm where you can purchase salads, sandwiches, drinks and other snacks

HALL A
Nov 2813:00
Conference pass

Start-up: A simple, safe, affordable, and scalable intradermal delivery platform for nucleic acid vaccines and therapeutics

Start-up Pitches
Gaurav Byagathvalli, Chief Executive Officer and co-founder, Piezo Therapeutics, Inc.
HALL B
Nov 2813:05
Conference pass

Start-up: Where innovation meets sustainability: Discover the Q-VANT breakthrough

Start-up Pitches
HALL B
Nov 2813:10
Conference pass

Start-up: Next Generation AI and saRNA and saDNA Platforms on Demand

Start-up Pitches
HALL B
Nov 2813:15
Conference pass

Start-up: MACH-1TM Epidermally Delivered Powdered Vaccine Platform

Start-up Pitches
HALL B
Nov 2813:45
Conference pass

Chair's Opening Remarks

Infectious Disease Vaccines
B4
Nov 2813:45
Conference pass

Chair's Opening Remarks

Cancer Immunotherapy
Maria Karasarides, Vice-President, Head Early Assets & Biomarkers, Bristol-Myers Squibb
B5
Nov 2813:45
Conference pass

Chair's Opening Remarks

Immune Profiling
Philip Felgner, Director, Vaccine R&D Center, University of California at Irvine
M2
Nov 2813:45
Conference pass
Nov 2813:45
Conference pass
Nov 2813:45
Conference pass
Nov 2813:50
Conference pass

A Phase 3 Study to Evaluate the safety, tolerability, and immunogenicity of V116, a pneumococcal conjugate vaccine designed for adults (STRIDE-3)

Infectious Disease Vaccines
B4
Nov 2813:50
Conference pass

Allogeneic EBV T-Cell Therapies: Ushering in the Next Wave of Innovation

Cancer Immunotherapy
B5
Nov 2813:50
Conference pass

High throughput analysis of B cell dynamics and neutralizing antibody development during HIV immunization

Immune Profiling
M2
Nov 2813:50
Conference pass

A Review of the Ring Trial Design for Evaluating Ring Interventions for Infectious Diseases

Clinical Trials
M1
Nov 2813:50
Conference pass

Development of a DNA-encoded monoclonal antibody for COVID-19

COVID-19 & Beyond
Diana Guimet, Principal Scientist, Inovio Pharmaceuticals
HALL B
Nov 2813:50
Conference pass

Development of Cloudbreak Drug-FC conjugates for the prevention of seasonal influenza

Antiviral Therapies
M3
Nov 2814:05
Conference pass

Understanding the immunogenicity of a 21-valent pneumococcal conjugate vaccine

Infectious Disease Vaccines
B4
Nov 2814:20
Conference pass

Development of 24-valent & next generation 31-valent PCV Vaccines

Infectious Disease Vaccines
B4
Nov 2814:20
Conference pass

Targeting HPV-positive anal, cervical, head and neck, penile, vaginal, vulvar cancers

Cancer Immunotherapy
B5
Nov 2814:20
Conference pass

Small protein mimetics of HIV-1 broadly neutralizing antibody epitopes represent promising tool for induction of HIV-1-neutralizing antibodies

Immune Profiling
M2
Nov 2814:20
Conference pass

Reducing protocol deviations and increasing data quality in vaccine trials

Clinical Trials
Eric Elander, Director of Business Development, Clinical Research IO (CRIO)
M1
Nov 2814:20
Conference pass

Engineered antibodies in the face of viral evolution

COVID-19 & Beyond
HALL B
Nov 2814:20
Conference pass

Encrypted RNA: A new class of RNA for inhalable & variant-proof immunity

Antiviral Therapies
M3
Nov 2814:35
Conference pass

From the Lab to the Jab and Back Again: AstraZeneca’s COVID-19 Monoclonal Antibody Response

COVID-19 & Beyond
HALL B
Nov 2814:50
Conference pass

Safety and Immunogenicity of a 21-valent Pneumococcal Conjugate Vaccine in Pediatric Population

Infectious Disease Vaccines
Sylvie PICHON, Global Clinical Development Strategy Expert, Sanofi
B4
Nov 2814:50
Conference pass

Clinical trials in HPV+ head and neck cancers

Cancer Immunotherapy
B5
Nov 2814:50
Conference pass

The pertussis puzzle: exploring the effectiveness of novel vaccination targets

Immune Profiling
M2
Nov 2814:50
Conference pass

Building a pipeline of black and diverse physician clinical research trial PIs

Clinical Trials
M1
Nov 2814:50
Conference pass

Boosting your defenses: The impact of additional covid-19 vaccine doses on t-cell responses

COVID-19 & Beyond
HALL B
Nov 2814:50
Conference pass

Predicting / profiling genetic barriers to resistance of antibody-based inhibitors

Antiviral Therapies
M3
Nov 2815:20
Conference pass

Targeting Staphylococcus aureus virulence for vaccination and immunotherapy

Infectious Disease Vaccines
B4
Nov 2815:20
Conference pass

Identification of immune modulating microbial proteins in cancer

Cancer Immunotherapy
B5
Nov 2815:20
Conference pass

Consultative design for influenza vaccine development – reverse genetics approaches for assay development and sample testing

Immune Profiling
M2
Nov 2815:20
Conference pass

Improving clinical trial recruitment

Clinical Trials
M1
Nov 2815:20
Conference pass

AI empowered infectious disease vaccine development

COVID-19 & Beyond
HALL B
Nov 2815:20
Conference pass

Taking a new route: Development of novel inhaled and oral influenza antiviral, CC-42344

Antiviral Therapies

Speaker TBC

M3
Nov 2815:35
Conference pass

Characterizing vaccine-induced immune responses with ELISpot and FluoroSpot assays

Immune Profiling
M2
Nov 2815:50
Conference pass

Exhibition & Partnering Break - Afternoon

Keynotes

Tea, Coffee and Refreshments served in the exhibition area

One-to-one networking meetings, Poster Presentations

So you can plan ahead there will be a Café station open in the exhibition from 8am-5pm where you can purchase tea, coffee and pastries until 11am, and then purchase hot food till 3pm.There will also be another open from 11am-3pm where you can purchase salads, sandwiches, drinks and other snacks

HALL A
Nov 2816:20
Conference pass

Safety & immunogenicity of MVX01 Pneumococcal Vaccine

Infectious Disease Vaccines
B4
Nov 2816:20
Conference pass

Facilitating multiple deliveries of therapeutic viruses by exploiting natural methods of evading neutralizing immunity

Cancer Immunotherapy
B5
Nov 2816:20
Conference pass

Characterization of broadly neutralizing mAbs against SARS-CoV-2 and influenza using a lentivirus pseudotype platform

Immune Profiling
M2
Nov 2816:20
Conference pass

Partnering for success within vaccine clinical trials

Clinical Trials
Tina Morgenstein, Project Director in the Vaccine Therapeutic Unit, PPD, Part of Thermo Fisher Scientific
M1
Nov 2816:20
Conference pass
Nov 2816:20
Conference pass

Remdesivir – a broad-spectrum antiviral and COVID-19 therapeutic

Antiviral Therapies
M3
Nov 2816:50
Conference pass

Panel: Beyond PCV13: Exploring the Future of Pneumococcal Disease Vaccines

Infectious Disease Vaccines
  • The current state of pneumococcal disease vaccine development and the limitations of PCV13.
  • New approaches to vaccine development, such as protein-based vaccines, conjugate vaccines, and combination vaccines
  • The potential impact of new vaccines on disease prevention and public health
  • Case for maternal immunization?
  • Challenges and opportunities for vaccine development in low- and middle-income countries
B4
Nov 2816:50
Conference pass

Novel Vaccinia Enhanced Template (VET) oncolytic platform

Cancer Immunotherapy
B5
Nov 2816:50
Conference pass

Multiplexed immune profiling for sars-cov-2 prevalence, asymptomatic infections and vaccine coverage

Immune Profiling
M2
Nov 2816:50
Conference pass

BPZE1 Induces Serum Bactericidal Activity against Pertactin-Positive and Pertactin-Deficient B. Pertussis

Clinical Trials
M1
Nov 2816:50
Conference pass

Panel: Bridging the divide - animal rule to clinical development

Antiviral Therapies
  • Use of pre-clinical models to inform licensure
  • Regulatory pathways
  • International coordination on clinical trials
M3
Nov 2817:20
Conference pass

MULTI-seq: lipid-conjugated DNA barcodes for multiplexed single-cell sequencing

Immune Profiling

Millipore Sigma

M2
Nov 2817:20
Conference pass

INO-3107 program for the treatment of Recurrent Respiratory Papillomatosis

Clinical Trials
M1

Create your personal agenda –check the favourite icon

Nov 298:20
Conference pass

Opening Keynote: Could antibodies be the principal tool with which we manage future viral pandemics?

Keynotes
HALL B
Nov 298:45
Conference pass

ASPR’s Office of Industrial Base Management and Supply Chain (IBMSC) - Domestic manufacturing for therapeutics and other critical medical products

Keynotes
HALL B
Nov 299:15
Conference pass

Keynote Panel: Moving to the left: The maturing applications of ct & cf DNA in oncology

Keynotes
  • What progress has been made? Recent approvals.
  • As yet untapped potential uses of ctDNA in oncology
  • Success in prediction but difficulty of use in later stage development
  • Do certain phenotypes amongst circulating immune cells dictate responsiveness to certain IO drugs or combinations?
Moderator: Maria Karasarides, Vice-President, Head Early Assets & Biomarkers, Bristol-Myers Squibb
Mohan Bolisetty, Associate Director, Bristol-Myers Squibb
HALL B
Nov 2910:15
Conference pass

Keynote Panel: SupeRNAtural: Realizing the potential of RNA therapeutics for ID & Cancer

Keynotes

There are a wide variety of RNA molecules used to inhibit infectious diseases and cancer, a discussion of the common challenges in:

  • Targeting multiple antigens simultaneously
  • Safety - More RNA = more side effects
  • Achieving equal expression
  • Delivering effective doses with lower amounts
  • Combination vaccines
  • Formulation
  • T-cells
HALL B
Nov 2911:15
Conference pass

Exhibition & Partnering Break - Morning

Keynotes

Tea, Coffee and Refreshments served in the exhibition area

One-to-one networking meetings, Poster Presentations

So you can plan ahead there will be a Café station open in the exhibition from 8am-5pm where you can purchase tea, coffee and pastries until 11am, and then purchase hot food till 3pm.There will also be another open from 11am-3pm where you can purchase salads, sandwiches, drinks and other snacks

HALL A
Nov 2911:45
Conference pass
Nov 2911:45
Conference pass

Chair's Opening Remarks

Cancer Immunotherapy
Michael Salgaller, Supervisor, Invention Development And Marketing Unit, National Cancer Institute - NIH
B5
Nov 2911:45
Conference pass
Nov 2911:45
Conference pass

Chair's Opening Remarks

COVID-19 & Beyond
HALL B
Nov 2911:45
Conference pass

Chair's Opening Remarks

Antiviral Therapies
M3
Nov 2911:45
Conference pass

Chair's Opening Remarks

Bioprocessing, Manufacture & Delivery
M1
Nov 2911:50
Conference pass

Late-stage maternal RSV vaccine development

Infectious Disease Vaccines
B4
Nov 2911:50
Conference pass

Priming cold tumors through GVAX and early development of mutated KRAS peptide & mRNA vaccines targeting multiple NeoAgs

Cancer Immunotherapy
B5
Nov 2911:50
Conference pass

Single cell analysis - Is it ready for the clinic?

Immune Profiling
Mohan Bolisetty, Associate Director, Bristol-Myers Squibb
M2
Nov 2911:50
Conference pass

PROTAC approach for antiviral drug discovery of coronaviruses

COVID-19 & Beyond
HALL B
Nov 2911:50
Conference pass

Hepatitis therapeutics and vaccines development

Antiviral Therapies
M3
Nov 2911:50
Conference pass

Supporting the development of vaccine manufacture in LMICs

Bioprocessing, Manufacture & Delivery
Robert Sitrin, Senior Scientist, PATH
M1
Nov 2912:20
Conference pass

Clinical development of an intranasal live attenuated RSV vaccine for infants

Infectious Disease Vaccines
B4
Nov 2912:20
Conference pass

Combination Vaccines (PD-1, PD-L1, CTLA-4, TIGIT, LAG3)

Cancer Immunotherapy
B5
Nov 2912:20
Conference pass

A cfDNA assay to monitor early escape

Immune Profiling
M2
Nov 2912:20
Conference pass

Ensitrelvir - an Oral 3CL Protease Inhibitor for the treatment of COVID-19

COVID-19 & Beyond
HALL B
Nov 2912:20
Conference pass
Nov 2912:20
Conference pass

Self-assembling nanoliposomal system, molecular adjuvants and mucoadhesive nanofibre based films for construction of recombinant vaccines

Bioprocessing, Manufacture & Delivery
M1
Nov 2912:50
Conference pass

From computationally designed antigens to VLP-based antigen display – a recipe for best-in-class vaccines

Infectious Disease Vaccines
B4
Nov 2912:50
Conference pass
Nov 2912:50
Conference pass

Immune profiling from blood in clinical trials

Immune Profiling
M2
Nov 2912:50
Conference pass

An ACE2 decamer viral trap by IgM frame as a durable solution for SARS-CoVs

COVID-19 & Beyond
HALL B
Nov 2912:50
Conference pass

Early development of novel anti-HBV ribonuclease H inhibitors

Antiviral Therapies
M3
Nov 2912:50
Conference pass

Applications of the MYO technology platform for DNA-Based antibody delivery

Bioprocessing, Manufacture & Delivery
M1
Nov 2913:20
Conference pass

Exhibition & Partnering Break - Lunch

Keynotes

Tea, Coffee and Refreshments served in the exhibition area

One-to-one networking meetings, Poster Presentations

So you can plan ahead there will be a Café station open in the exhibition from 8am-5pm where you can purchase tea, coffee and pastries until 11am, and then purchase hot food till 3pm.There will also be another open from 11am-3pm where you can purchase salads, sandwiches, drinks and other snacks

HALL A
Nov 2914:30
Conference pass

Computational bioengineering of broad-spectrum mRNA LNP vaccines

Infectious Disease Vaccines
B4
Nov 2914:30
Conference pass

Merck/Moderna cancer vaccine combination study

Cancer Immunotherapy
B5
Nov 2914:30
Conference pass

In situ tumor arrays reveal early environmental control of cancer immunity

Immune Profiling
M2
Nov 2914:30
Conference pass

Broadly acting cathepsins inhibitors against COVID-19 and emerging infectious diseases

COVID-19 & Beyond
HALL B
Nov 2914:30
Conference pass

Clinical updates for NAPs in HBV and HDV: multiyear follow-up from phase II studies and compassionate use in cirrhotic patients

Antiviral Therapies
M3
Nov 2914:30
Conference pass

Redefining Access: Prefilled injectables for safe and efficient vaccinations

Bioprocessing, Manufacture & Delivery
M1
Nov 2915:00
Conference pass

How Human challenge studies facilitate effective vaccine transmission blocking efficacy testing

Infectious Disease Vaccines

Senior Representative, hVIVO

Andrew Catchpole, CSO, hVIVO
B4
Nov 2915:00
Conference pass

Demonstration of a universal preventative cancer vaccine

Cancer Immunotherapy
B5
Nov 2915:00
Conference pass

Linked CD4+/CD8+ T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression

Immune Profiling
M2
Nov 2915:00
Conference pass

Discovery & development of small molecule viral assembly modulators against respiratory pathogens

COVID-19 & Beyond
Vishwanath Lingappa, Chief Executive Officer, Chief Technology Officer And Member Board Directors, Prosetta Biosciences
HALL B
Nov 2915:00
Conference pass

Addressing the Unmet Need for a Functional Cure for Chronic Hepatitis B

Antiviral Therapies
M3
Nov 2915:00
Conference pass

Sustainable production of Quillaja saponins for vaccine adjuvants

Bioprocessing, Manufacture & Delivery
M1
Nov 2915:30
Conference pass

Use of adjuvants to drive appropriate immune responses to respiratory disease vaccines; Pertussis, TB, COVID

Infectious Disease Vaccines
B4
Nov 2915:30
Conference pass

AMPLIFY Vaccine Platform: repRNA + LION™

Cancer Immunotherapy
B5
Nov 2915:30
Conference pass

JO – opening tumor junctions to treat cancer

Immune Profiling
M2
Nov 2915:30
Conference pass

Development of small bispecifc drugs targeting influenza and other respiratory diseases

COVID-19 & Beyond
HALL B
Nov 2915:30
Conference pass

Advancing CARG-201, a self-amplifying mRNA vaccine for immunotherapy of chronic hepatitis B, from animal models to clinical trials

Antiviral Therapies
M3
Nov 2915:30
Conference pass

Securing a Resilient Future: Sustainable Supply of Saponins for Global Vaccine Development

Bioprocessing, Manufacture & Delivery
M1
Nov 2916:00
Conference pass

Exhibition & Partnering Break - Afternoon

Keynotes

Tea, Coffee and Refreshments served in the exhibition area

One-to-one networking meetings, Poster Presentations

HALL A
Nov 2916:30
Conference pass

BPZE1, an intranasal live attenuated pertussis vaccine, evaluated in a bordetella pertussis challenge study in healthy adults: a phase 2b, randomized, placebo-controlled study

Infectious Disease Vaccines
B4
Nov 2916:30
Conference pass

Furthering innovative ideas in oncology through NCIs PREVENT Network

Immune Profiling
M2
Nov 2916:30
Conference pass

Development of an Oral, Broad-Spectrum Antiviral Therapeutic for Respiratory Viruses

COVID-19 & Beyond
HALL B
Nov 2916:30
Conference pass

Panel: Toward a Hepatitis B-Free Future: Perspectives on Achieving a Functional Cure

Antiviral Therapies
    li>
  • How do you define a functional / partial cure – how should we use these terms and what are their limitations?

  • Which technologies/ modalities are we using to achieve a functional cure? What are the limits of different approaches? Can they be combined for more therapeutic benefit? (Antivirals, Antibodies, Vaccines, siRNA

  • Components to an effective cure strategy:

    o Use of viral replication inhibitors

    o Reducing viral surface antigen load – do we still have room to further reduce load?

    o Activation of antiviral immune response

  • Challenges in balancing side-effects and therapeutic efficacy

    How do we manage / avoid resistance

M3
Nov 2916:30
Conference pass
Nov 2917:00
Conference pass

Moving From the Lab to the Clinic: Clinical Implementation Challenges of CPG, MRD and Screening

Immune Profiling
M2

Create your personal agenda –check the favourite icon

Nov 308:40
Conference pass

Keynote Panel: Beyond Borders: Collaborating for success in developing vaccines for emerging infectious diseases

Keynotes
  • Challenges around stock piling vaccines that are not yet licensed –
    • need for (relatively small) stockpiles of “vialed and quality-tested vaccines that are ready to be clinically tested in populations as soon as the next outbreak strikes”.
    • Is stockpiling the victim of market failure?
    • Funding mechanisms decoupled from the market
  • Aligning programmatic interests during outbreaks and “peace times
    • Experiences getting Sudan Ebola vaccines to Uganda
  • Alternative regulatory pathways and accelerated development
  • Aligning interests & objectives of international funding partners
HALL B
Nov 309:40
Conference pass

Keynote Panel: Platforms of the future: from precision therapies to synthetic immune systems

Keynotes
  • Could new platform technologies enable us to develop countermeasures rapidly enough to stop emerging viral threats before pandemics ensue?
  • Are broad-spectrum (pan-variant) prophylactics a possible way forward?
  • When will we see the first clinically approved mRNA or DNA-encoded therapeutics, from gene-editing to immunotherapy?
  • Could advances in AI and synthetic biology enable personalized medicines (e.g. for cancers) to be developed at a population scale?
  • Would regulators agree to accelerate approval of platform-based medicines based on the safety and efficacy of different candidates from the same platform?
  • Can Government, biopharma, and venture capital co-fund platform technologies, especially for technologies of dual commercial and national security interest?
HALL B
Nov 3010:40
Conference pass

Exhibition & Partnering Break - Morning

Keynotes

Tea, Coffee and Refreshments served in the exhibition area

One-to-one networking meetings, Poster Presentations

So you can plan ahead there will be a Café station open in the exhibition from 8am-5pm where you can purchase tea, coffee and pastries until 11am, and then purchase hot food till 3pm.There will also be another open from 11am-3pm where you can purchase salads, sandwiches, drinks and other snacks

HALL A
Nov 3011:10
Conference pass

Chair's Opening Remarks

Infectious Disease Vaccines
Jessica Malaty Rivera, Research Assistant, Johns Hopkins Center For Health Security
B4
Nov 3011:10
Conference pass

Chair's Opening Remarks

Antiviral Therapies
M3
Nov 3011:10
Conference pass

Chair's Opening Remarks

New Technology
M1
Nov 3011:10
Conference pass
Nov 3011:15
Conference pass

Vaccine development programs for emerging infectious diseases; lassa, marbug, Ebola Sudan

Infectious Disease Vaccines
B4
Nov 3011:15
Conference pass

LOQTORZITM (toripalimab-tpzi) – a next generation PD-1 inhibitor

Cancer Immunotherapy
B5
Nov 3011:15
Conference pass

Development of broad-spectrum protease inhibitors to combat emerging viral diseases

Antiviral Therapies
Byron Martina, Protinhi Therapeutics
M3
Nov 3011:15
Conference pass

Sera from mice vaccinated with Epstein-Barr virus-like particles potently prevent infection of human B cells and epithelial cells in vitro

New Technology
M1
Nov 3011:15
Conference pass

Panel: De-risking therapeutics drug development for infectious diseases –

Partnerships
  • Road to repurposing and expanding use of broad-spectrum antivirals
  • Setting up public private partnerships
  • Alignment of interests
  • Commercial risks of clinical trials
Kashmira Date, Global Medical Affairs Lead - Vaccines, Johnson and Johnson Global Public Health
Diane Griffin, Vice President, National Academy of Sciences, Professor, Molecular Microbiology And Immunology, Johns Hopkins Bloomberg School of Public Health
M2
Nov 3011:45
Conference pass

TB vaccine development: From clinical trials to market access - current status and future perspectives

Infectious Disease Vaccines
B4
Nov 3011:45
Conference pass

Progress in the clinical development of bispecific t-cell engagers as monotherapies and in combination

Cancer Immunotherapy
B5
Nov 3011:45
Conference pass

Identification of small molecule inhibitors against the nsP2 protease (nsP2pro) of Chikungunya virus

Antiviral Therapies
M3
Nov 3011:45
Conference pass

Targeting HIV-1 and Beyond: Novel Protein Nanoparticles as Vaccine Platforms

New Technology
M1
Nov 3012:15
Conference pass

Early development of next generation malaria VLP vaccines that target vulnerable epitopes

Infectious Disease Vaccines
Bryce Chackerian, Professor, University of New Mexico School of Medicine
B4
Nov 3012:15
Conference pass

Development of cancer immunotherapies targeting the STING pathway

Cancer Immunotherapy
Glen Barber, Chief Executive Officer, STINGINN; Chairman and Professor, Department of Cell Biology, University of Miami
B5
Nov 3012:15
Conference pass

Identification of broad-spectrum antivirals for emerging viral diseases

Antiviral Therapies
Vaithilingaraja Arumugaswami, Co-Founder, Veergen Inc. ; Professor, Department of Molecular and Medical Pharmacology, University of California, Los Angeles
M3
Nov 3012:15
Conference pass

Development of saponin-based adjuvant IA-05 for subunit-vaccines

New Technology
Richard Guy, Global Business Development, ImmunAdd Inc.
M1
Nov 3012:15
Conference pass

Fireside chat: Engaging with public-private partnerships to accelerate multi-use technologies with commercial and preparedness applications

Partnerships

Innovation is a journey that can be complex and unpredictable, but it does not have to follow a singular path. Leveraging opportunities to collaborate with multiple stakeholders, including through public-private partnerships, can accelerate innovation and yield unique advantages.

During this session, Dr.Michael Egan, CEO of CastleVax, will share insights on how the CastleVax technology has been accelerated by leveraging opportunities such as New York State funding, incubation through BLUE KNIGHT™ at JLABS @ NYC, partnering with another BLUE KNIGHT™ company to be awarded $1M through the BLUE KNIGHT™ Resident QuickFire Challenge: Accelerating Project NextGen, and a Project NextGen award to support a phase 2b clinical trial.

In a conversation with Dan Wolfe, Branch Chief, CBRN Vaccines at BARDA, the discussion will highlight leveraging complementary opportunities to accelerate next generation potential solutions and how BARDA engages in public-private partnerships to support early-stage companies.

Michael Egan, CEO/CSO, CastleVax
Kashmira Date, Global Medical Affairs Lead - Vaccines, Johnson and Johnson Global Public Health
M2
Nov 3012:45
Conference pass

Exhibition & Partnering Break

Keynotes

Tea, Coffee and Refreshments served in the exhibition area

One-to-one networking meetings, Poster Presentations

So you can plan ahead there will be a Café station open in the exhibition from 8am-5pm where you can purchase tea, coffee and pastries until 11am, and then purchase hot food till 3pm.There will also be another open from 11am-3pm where you can purchase salads, sandwiches, drinks and other snacks

HALL A
Nov 3013:45
Conference pass

Design and evaluation of vaccines against hemorrhagic fevers using the MVA-VLP platform

Infectious Disease Vaccines
B4
Nov 3013:45
Conference pass

PRISM™ Platform: physics-based drug design for oncology & infectious disease

Cancer Immunotherapy
B5
Nov 3013:45
Conference pass

Partnerships To Address Emerging Health Threats: The urgent need for antivirals

Antiviral Therapies
Kashmira Date, Global Medical Affairs Lead - Vaccines, Johnson and Johnson Global Public Health
M3
Nov 3013:45
Conference pass

Development of CPMV-based vaccines against cancer

New Technology
M1
Nov 3013:45
Conference pass

Advancing R&D of long COVID & post-viral diseases through public-private partnerships

Partnerships
M2
Nov 3014:15
Conference pass

Early development of vaccines against Nairovirus (CCHF) and Nipah Virus

Infectious Disease Vaccines
B4
Nov 3014:15
Conference pass

Small molecule protein assembly modulators with pan-cancer therapeutic efficacy

Cancer Immunotherapy
B5
Nov 3014:15
Conference pass

Anticancer pan-ErbB inhibitors reduce inflammation and tissue injury and exert broad-spectrum antiviral effects

Antiviral Therapies
M3
Nov 3014:15
Conference pass

A novel molecular clamp subunit vaccine platform

New Technology
M1
Nov 3014:15
Conference pass

The evolution of task forces & initiatives to address Hepatitis C nationally & internationally

Partnerships
M2
Nov 3014:45
Conference pass

The Long and Winding Road to the mRNA Vaccine

New Technology
Philip Felgner, Director, Vaccine R&D Center, University of California at Irvine
M1
Nov 3014:45
Conference pass

How can an Intellectual Property International Consortium (IPIC) benefit small biotechs? *Title TBC

Partnerships
M2
Nov 3015:00
Conference pass

Biopharmaceutical Stocks—Out of favor, yet impressive Pipelines

Partnerships
M2
Nov 3015:20
Conference pass

Closing Keynote Panel: The Vaccine Wars: Why vaccine mandates are more complex than you think

Keynotes
Richard Pan, Senior Policy Advisor, Board Member, Pediatrician, Former CA State Senator, Public Health Advocate, California Department of Health Care Access and Information
B4
last published: 02/Jan/24 12:15 GMT